Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells

BMC Veterinary Research

Magdalena Król²  Tomasz Motyl²  Kinga Majchrzak³  Joanna Mucha²  Karol M Pawłowski¹ 

[1] Department of Large Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences – WULS, Nowoursynowska 100, 02-797, Warsaw, Poland;Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences - WULS, Nowoursynowska 159, 02-776, Warsaw, Poland;Department of Animal Environment Biology, Faculty of Animal Sciences, Warsaw University of Life Sciences - WULS, Ciszewskiego 8, 02-786, Warsaw, Poland

关键词: MRP3;    MRP1;    BCRP;    PGP;    Cyclophosphamide;    Cisplatin;    Vinblastine;    Canine mammary cancer;    Chemotherapy;    Multidrug resistance;   

Others  :  1119519
DOI  :  10.1186/1746-6148-9-119

 received in 2013-01-12, accepted in 2013-06-13,  发布年份 2013

【 摘 要 】

Background

In both women and female dogs, the most prevalent type of malignant neoplasm is the spontaneous mammary tumor. In dogs, half of these are malignant. The treatment of choice for the canine patients is surgical mastectomy. Unfortunately, it often fails in high-risk, locally invasive mammary tumors as of during the time of the surgery the micro-metastases are present. Moreover, there are neither large studies conducting to prove of the benefit from the chemotherapy in dogs nor established chemotherapy treatment protocols available. Additionally, the effectiveness of each individual chemotherapeutic agent and drug resistance of canine mammary cancer have not yet been characterized. That has become the aim of our study, to assess the expression of PGP, BCRP, MRP1 and MRP3 in canine mammary cancer cell lines and to investigate their role in cancer resistance to vinblastine, cisplatin and cyclophosphamide with using RNAi approach.

Results

The results suggested that in canine mammary cancer, the vinblastine efflux was mediated by PGP and MRP1 proteins, cisplatin efflux was mediated by all four examined efflux pumps (PGP, BCRP, MRP1 and MRP3), whereas cyclophosphamide resistance was related to BCRP activity. RNAi silencing of these efflux pumps significantly decreased IC50 doses of the examined drugs in canine mammary carcinoma cells.

Conclusions

Our results have indicated the treatment of cells involving use of the siRNA targeting efflux pumps could be a beneficial approach in the future.

【 授权许可】

   
2013 Pawłowski et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]MacEwen EG: Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990, 9:125-136.
• [2]Midsorp W: Tumors of the mammary gland. In Tumors in domestic animals. Edited by Meuten DJ. Ames: Iowa State Press; 2002:575-606.
• [3]Misdorp W: Progestagens and mammary tumours in dogs and cats. Acta Endocrinol 1991, 125(Suppl. 1):27-31.
• [4]Stratmann N, Failing K, Richter A, Wehrend A: Mammary tumor recurrence in bitches after regional mastectomy. Vet Surg 2008, 37:82-86.
• [5]Simon D, Schoenrock D, Baumgartner W, Nolte I: Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 2006, 20:1184-1190.
• [6]Marconato L, Lorenzo RM, Abramo F, Ratto A, Zini E: Adjuvant gemcitabine after removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol 2008, 6:90-101.
• [7]Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A: Adjuvant post-operative chemotherapy in bitches with mammary cancer. Transbound Emerg Dis 2001, 48:85-96.
• [8]Król M, Pawłowski KM, Majchrzak K, Szyszko K, Motyl T: Why chemotherapy can fail? Pol J Vet Sci 2010, 12:399-406.
• [9]Szyszko K, Pawłowski KM, Motyl T, Król M: Chemoresistance in cancer: not just a humans problem. Med Wet 2011, 67(7):453-457.
• [10]Honscha KU, Schirmer A, Reischauer A, Schoon HA, Einspanier A, Gabel G: Expression of ABC-transport proteins in canine mammary cancer: consequences for chemotherapy. Reprod Domest Anim 2009, 44:218-223.
• [11]Roth BJ, Sledge GW, Williams SD, Meyer SC, Ansari R, Fisher WB: Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in metastatic breast cancer. Cancer 1991, 68:248-252.
• [12]Briest S, Stearns V: Chemotherapeutic strategies for advanced breast cancer. Oncology 2007, 21(11):1325-1335.
• [13]Ospovat I, Siegelmann-Danieli N, Grenader T, Hubert A, Hamburger T, Peretz T: Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients. Tumori 2009, 95(6):683-686.
• [14]Whitehead KA, Langer R, Anderson DG: Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discovery 2009, 8:129-138.
• [15]Król M, Pawłowski KM, Majchrzak K, Gajewska M, Majewska A, Motyl T: Global gene expression profiles of canine macrophages and canine mammary cancer cells grown as a co-culture in vitro. BMC Vet Res 2012, 8:16. BioMed Central Full Text
• [16]Król M, Pawłowski KM, Skierski J, Rao NAS, Hellmen E, Mol JA, Motyl T: Transcriptomic profile of two canine mammary cancer cell lines with different proliferative and anti-apoptotic potential. J Physiol Pharmacol 2009, 60:95-106.
• [17]Król M, Pawłowski KM, Skierski J, Turowski P, Majewska A, Polańska J, Ugorski M, Morty RE, Motyl T: Transcriptomic “portraits” of canine mammary cancer cell lines with various phenotype. J Appl Genet 2010, 51:169-183.
• [18]Król M, Polańska J, Pawłowski KM, Skierski J, Majewska A, Ugorski M, Motyl T: Molecular signature of cell lines isolated from mammary adenocarcinoma metastases to lungs. J Appl Genet 2010, 51:37-50.
• [19]Pawłowski KM, Popielarz D, Szyszko K, Motyl T, Król M: Growth Hormone Receptor RNA interference decreases proliferation and enhances apoptosis in canine mammary carcinoma cell line CMT-U27. Vet Comp Oncol 2012, 10(1):2-15.
• [20]Majchrzak K, Pawlowski KM, Orzechowska EJ, Dolka I, Mucha J, Motyl T, Król M: A role of ghrelin in canine mam mary carcinoma cells proliferation, apoptosis and migration. BMC Vet Res 2012, 8:170. BioMed Central Full Text
• [21]Król M, Majchrzak K, Mucha J, Homa A, Bulkowska M, Jakubowska A, Karwicka M, Pawłowski KM, Motyl T: CSF-1R as an inhibitor of apoptosis and promoter of proliferation, migration and invasion of canine mammary cancer cells. BMC Vet Res 2013, 9:65. BioMed Central Full Text
• [22]Brinkhof B, Spee B, Rothuizen J, Penning LC: Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem 2006, 356:36-43.
• [23]Etschmann B, Wilcken B, Stoevesand K, von der Schulenburg A, Sterner-Kock A: Selection of reference genes for quantitative real-time PCR analysis in canine mammary tumors using the GeNorm algorithm. Vet Pathol 2006, 43:934-942.
• [24]Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative Ct method. Nature Prot 2008, 3:1101-1108.
• [25]Palmeira A, Vasconcelos MH, Paiva A, Fernandes MX, Pinto M, Sousa E: Dual inhibitors of P-glycoprotein and tumor cell growth: (Re)discovering thioxanthones. Biochem Pharmacol 2012, 83:57-68.
• [26]Nalbantsoy A, Karabay-Yavasoglu NU, Sayim F, Deliloglu-Gurhan I, Gocmen B, Arikan H, Yildiz MZ: Determination of in vivo toxicity and in vitro cytotoxicity of venom from the Cypriot blunt-nosed viper Macrovipera lebetina lebetina and antivenom production. JVATiTD 2012, 18:208-216.
• [27]Grube S, Langguth P: Modulation of drug-carrier activity by excipients. In Drug delivery research advances. Edited by Mashkevich BO. New York: Nova Science Publishers, Inc; 2007:81-104. ISBN 978-1-60021-732-6
• [28]Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ: Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 2004, 10:RA5-RA14.
• [29]Creasey W, Scott AI, Wei CC, Kutcher J, Schwartz A, Marsh JC: Pharmacological studies with Vinblastine in the dog. Cancer Res 1975, 35:1116-1120.
• [30]Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y: Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release 2009, 137(1):63-68.
• [31]Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, Roe DJ: Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res 1987, 47:2723-2726.